With U.S. Patent No. 12,187,679 now granted, Enveric Biosciences has secured more than intellectual property—it’s staked a claim on the future of neurotherapeutics. The Cambridge-based biotech firm announced this week…
Read More
The psychedelic industry stands at the cusp of a transformative era, propelled by the development of next-generation molecules with the potential to be more effective treatments for a host of…
Read More
In a significant development for mental health treatments, Enveric Biosciences (NASDAQ: ENVB) has secured its first U.S. patent for a novel series of compounds that could transform how we approach neuropsychiatric disorders. The company’s…
Read More
Enveric Biosciences has secured its first U.S. patent for the EVM401 Series, a novel collection of non-hallucinogenic, mescaline-derived compounds. These compounds are designed to address addiction, ADHD anxiety, and other…
Read More
New patent for mescaline derivative compounds broadens Enveric's potential to develop neuroplastogen therapeutics for addiction and neuropsychiatric disorders CAMBRIDGE, Mass. - Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a…
Read More
The treatment landscape for joint diseases like osteoarthritis and rheumatoid arthritis is poised for a significant breakthrough, thanks to an innovative licensing deal between Enveric Biosciences and Restoration Biologics. The…
Read More
On Tuesday, Enveric Biosciences’ wholly-owned subsidiary, Akos Biosciences, Inc., entered into two licensing agreements with Restoration Biologics LLC, a biotechnology company focused on treating joint disease. The companies have executed…
Read More
Enveric Biosciences announced the issuance of two new patents from the US Patent and Trademark Office (USPTO) supporting its EVM301 and EVM201 series compounds. These patents increase the total number…
Read More
Psychedelics biotech company Enveric Biosciences completed preclinical pharmacokinetic (PK) studies for its leading drug candidate EB-003 aimed at treating depression and anxiety without causing hallucinations. EB-003 is a neuroplastic and…
Read More
Enveric Biosciences (NASDAQ: ENVB) agreed to license one of its experimental psychedelic drug candidates to MycoMedica Life Sciences in a deal worth as much as $62 million, as the biotech…
Read More
